Report topline data for DARE-HRT1 Phase 1 study
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 11 Jan 2021
- Due
- 31 Dec 2021
- Delivered
- June 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Topline data for DARE-HRT1 Phase 1 study”
What we found
Evidence strength A What the grades mean
The company reported positive topline data from the Phase 1 clinical study of DARE-HRT1 in 2021, meeting the commitment to report data by the end of that year.
-
A Dare Bioscience, Inc. 10-Q filed 2022-05-12
“In 2021, we reported positive topline data from a Phase 1 clinical study that evaluated the PK of the same two versions of DARE-HRT1 over 28 days.” ✓ confirmed on the page
-
A Dare Bioscience, Inc. 10-K filed 2023-03-30
“We previously announced positive topline results from the study in June 2021.” ✓ confirmed on the page
Market reaction: the shares moved +18.3% against the S&P 500 over the three sessions around the disclosure (11 May 2022 to 16 May 2022). What this measures
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- DARE-HRT1 Phase 1 topline data
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Dare Bioscience, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-DARE-021721 · Corrections policy